Transactions

Deal Showcase

About Transactions

SVB Securities Serves as Joint Bookrunner for Prometheus Biosciences’ (Nasdaq: RXDX) $500 Million Follow-On Offering

Published: December 2022
Share Print Download
Biopharma DNA strand composition

More Transactions

$125 Million
Joint Bookrunner
Follow-On
February 2023
$119 Million
Joint Bookrunner
Follow-On
October 2021
$150 Million
Joint Bookrunner
Follow-On
December 2023
$35 Million
Exclusive Financial Advisor
Series C Financing Led by MultiPlan Corporation
June 2022
View all Transactions

Featured Insights

VIEW ADDITIONAL INSIGHTS
Banner desktop

Partner With Us

Let us help you achieve your strategic,
capital markets, and investment objectives

Contact Us

Our experienced team is happy to assist you. Please complete the form below and we’ll be in touch as soon as possible. “*” indicates required fields

Consent(Required)
This field is for validation purposes and should be left unchanged.